🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

NET-TIME: Inflammatory Tumor Microenvironment in Pituitary Neoplasm

Recruitingn/aAges 18 Years - 100 YearsAllFondazione Policlinico Universitario Agostino Gem…
NCT07594262 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Over the past twenty years, a progressively increasing number of markers biochemical, clinical, imaging, histopathological or genetic have been suggested to attempt to predict aggression and therapeutic outcome, both in secretory PitNETs and in non-secretory PitNETs. In recent years, the microenvironment tumor (TEM) has been extensively studied in different malignancies, promoting the development of therapies target and immunotherapy with checkpoint inhibitors immune system (ICI). Data on TIME in PitNETs are scarce today and derive from studies conducted mainly on heterogeneous cases for type of PitNET. Therefore, the purpose of this research project is to investigate the TIME in PitNET, to identify immune biomarkers and new molecular pathways that can promote the use of ICI and target therapies in Aggressive PitNETs.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * indication as per clinical practice and in agreement to current guidelines for surgical removal of the PitNET0; * patient naïve to medical therapy before surgical removal of PitNET; * Diagnosis of PitNET confirmed through the study pathological/histological; * over 18 years of age; * acceptance of participation in the study, by signing an informed consent. Exclusion Criteria: * History of medical therapy with analogs of somatostatin or dopamine agonist, previous the removal of the pituitary adenoma; * history of radiotherapy of the head and neck region earlier than 10 years after resection of the adenoma pituitary; * history of autoimmune diseases.
💊

What it tests

  • Not listed
📍

Where

1 site
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC ENDOCRINOLOGIA
Rome, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy